(Q34293779)

1 August 2017

1 reference

title

Efficacy of antileukotriene agents in asthma management (English)

1 reference

1 August 2017

0 references

R A Nathan

1

1 reference

1 August 2017

J P Kemp

series ordinal

2

1 reference

1 August 2017

Antileukotriene Working Group

series ordinal

3

1 reference

1 August 2017

publication date

1 June 2001

1 reference

Annals of Allergy, Asthma & Immunology

1 August 2017

published in

1 reference

1 August 2017

volume

86

1 reference

1 August 2017

issue

6 Suppl 1

1 reference

1 August 2017

page(s)

9-17

1 reference

Pathology of asthma and its clinical implications

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Leukotrienes and lipoxins: structures, biosynthesis, and biological effects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Translocation of cytosolic phospholipase A2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Leukotriene E4 and granulocytic infiltration into asthmatic airways

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Adverse effects of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962306-X

7 January 2021

10.1016/S1081-1206(10)62306-X

Identifiers

DOI

1 reference

1 August 2017

1 reference